Switzerland's Idorsia posts Q1 loss as high QUVIVIQ sales more than offset by costs, lack of one-time gain

Idorsia

28/04/2026 06:15

Overview

Switzerland biopharma firm's Q1 net revenue fell yr/yr, driven by lower contract revenue

QUVIVIQ sales rose 74% yr/yr to CHF 44 mln, reflecting continued global expansion

Company posted Q1 net loss of CHF 46 mln, impacted by higher financial expenses and absence of prior-year gain

Outlook

Idorsia maintains 2026 guidance: QUVIVIQ sales of CHF 200 mln, non-GAAP operating loss of ~CHF 120 mln

Company expects QUVIVIQ sales to grow about 50% in North America and Europe vs 2025

TRYVIO/JERAYGO revenues and investments excluded from guidance pending partnership agreements

Result Drivers

QUVIVIQ SALES GROWTH - QUVIVIQ net sales rose 74% yr/yr to CHF 44 mln, driven by expanded market launches, co-promotion agreements, and broader reimbursement in Europe and North America

PEDIATRIC DATA - Company reported strong Phase 2 results for daridorexant in children with insomnia, with plans to publish and discuss with regulators

TRYVIO/JERAYGO UPTAKE - TRYVIO/JERAYGO saw increasing use among specialists and in academic centers, with ongoing partnering discussions

Company press release: ID:nGNE4zvQt7

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
CHF 57 mln
Q1 EPS
-CHF 0.18
Q1 Net Income
-CHF 46 mln
Q1 Basic EPS
-CHF 0.18
Q1 EBIT
-CHF 26 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Idorsia Ltd is CHF4.50, about 19.6% above its April 27 closing price of CHF3.76

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)